
John Ramunas, PhD
CEO
Rejuvenation Technologies Inc.
I co-invented telomerase reverse transcriptase (“TERT”) mRNA-based telomere extension during my graduate work in the laboratory of Dr. Helen Blau at Stanford University. I believe so strongly in the therapeutic value of our invention that, after obtaining my Ph.D., I remained in Dr. Blau’s lab as a postdoctoral researcher and in 2016 we co-founded a company, Rejuvenation Technologies Inc., to make TERT mRNA available to patients. The importance of our invention is evidenced by our receipt of an NIH Transformative Grant to apply our invention to the treatment of disease. In addition, based in part on our successes applying TERT mRNA in vivo, our company, Rejuvenation Technologies Inc., has raised over $10,000,000 in venture capital funding from experienced investors such as Khosla Ventures and Y Combinator, resulting in two clinical candidates on track to being Phase 1 clinical trials in 2024 and 2025, respectively. Our goal is to bring TERT mRNA-based telomere extension to the patients who need it.